Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Unknown 4

Sponsor Class

INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 64Colorectal Neoplasms 58Rectal Neoplasms 46Stomach Neoplasms 44Neoplasm Metastasis 16Pancreatic Neoplasms 15Colonic Neoplasms 13Triple Negative Breast Neoplasms 11Neoplasms 11Esophageal Neoplasms 9Nasopharyngeal Carcinoma 8Locally Advanced Rectal Cancer 7Esophageal Squamous Cell Carcinoma 7Cholangiocarcinoma 6Biliary Tract Neoplasms 6Carcinoma, Hepatocellular 5HER2 Positive Metastatic Breast Cancer 4Colorectal Cancer Metastatic 4Adenocarcinoma 4Solid Tumor 3Recurrence 3Gallbladder Neoplasms 3Anus Neoplasms 3Advanced Breast Cancer 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Neuroendocrine Tumors 2Locally Advanced Colon Cancer 2Hyperthermia 2Head and Neck Neoplasms 2

Interventions

pyrotinib 4Capecitabine 4Lapatinib 2Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × HER2 Positive Metastatic Breast Cancer × Capecitabine × Clear all
NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Henan Cancer Hospital

Phase 2 Unknown
78 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT02973737 2022-10-25

A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
279 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT03080805 2020-06-18

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
240 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT02422199 2018-07-09

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
128 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡